As a new-type foreign trade service provider driven by both technology transformation and foreign trade services, HiSiaddi has established a "1+2+3+4=1" service system and can supply raw materials of Pueraria Mirifica extract from multiple well-known original manufacturers. Possessing R&D capabilities, HiSiaddi has repeatedly resolved customized product demands for Pueraria Mirifica extract through technological transformation cooperation with manufacturers and accurate insight into market demands. Below is a case of HiSiaddi fulfilling customized demands for Pueraria Mirifica extract products.
If you require more customized service solutions, please contact HiSiaddi customer service.
The purchaser is BioSalud S.L. based in Barcelona, Spain, a mid-to-high-end pharmaceutical enterprise on the Iberian Peninsula specializing in cardiovascular dietary preparations and premium hangover relief & liver-protecting oral liquids. Its full line of Pueraria soft capsules and botanical beverages are sold in national chain pharmacies, private wellness hospitals across Spain, and premium organic supermarkets in Portugal. For raw material access, the enterprise complies with five major compliance standards: EU EC396 covering 226 pesticide residue items, USP Pharmacopoeia, LFGB food raw material specifications, REACH chemical control regulations, and EUDR plant traceability rules. Its formulas are included in Spain’s domestic catalog of natural medicinal raw materials.
Previously, the enterprise sourced standardized Pueraria Mirifica extract from natural raw material manufacturers in France for a long time. Affected by reduced domestic raw material harvests in Europe, a 42% cumulative price hike over two consecutive years, and extended lead times for customized orders overseas, it developed a China-based customized raw material supply chain in 2025 with an annual total customized procurement volume of 16.5 tons, split into two types of non-standard customized raw materials:
1. High-purity Pueraria powder for pharmaceutical capsules: total isoflavones ≥40%, puerarin ≥22%, free of exogenous fillers such as starch, dextrin and maltodextrin, with ethanol solvent residue ≤2800 ppm;
2. Cold-water instant modified Pueraria powder for oral liquids: instantly soluble in cold water at room temperature, free of flocculent precipitation and stratification after 90 days of storage at 4°C, compatible with sterile oral liquid mass production lines.
The client independently contacted four domestic plant extract manufacturers in China to send samples and conduct small-batch trial production. After seven batches of raw materials were delivered to its GMP production workshop in Spain for trial manufacturing, five major customization problems emerged one after another: unstable active ingredient content due to mixed raw material origins, puerarin degradation caused by high-temperature extraction, poor powder solubility leading to precipitation, excessive starch impurities, and incomplete EU compliance documentation. The new product launch schedule was delayed by 76 days, with losses from sample testing, wasted auxiliary materials and production line shutdowns totaling 21,700 Euros.
Most domestic cooperating manufacturers mass-produce standard domestic bulk Pueraria raw materials via traditional high-temperature ethanol extraction and crude spray-drying processes. They lack capabilities including controlled GAP Pueraria raw material sourcing, low-temperature refining, directional powder modification, and EU compliance filing, and can only produce products according to their own conventional specifications, failing to meet the client’s personalized non-standard customization parameters. Upon recommendation by the Spanish Natural Plant Raw Materials Association, the client fully entrusted HiSiaddi to coordinate the full-process customized delivery service covering designated raw material collection, customized extraction process debugging, powder modification by dosage form, and full-chain EU compliance support.
Previous suppliers purchased raw materials from scattered sources, randomly mixing wild Pueraria from mountainous areas of Hubei, artificially cultivated starch Pueraria from Guangxi, and aged residual Pueraria from Jiangxi for feeding. The intrinsic total isoflavone content of standardized 3-year wild Pueraria from Hubei reaches 7.5%–8.2%, while fast-growing starch Pueraria from Guangxi only contains 3.8%–4.5%. The feeding ratio was adjusted arbitrarily based on raw material procurement costs, resulting in finished product total isoflavone levels ranging wildly from 32.7% to 42.1%, and puerarin fluctuating between 17.2% and 23.5%, failing to stably hit the mandatory target of puerarin ≥22%. HPLC detection chromatograms showed numerous miscellaneous peaks, with uncontrollable polysaccharide and colloid impurity levels. The Spanish pharmaceutical plant could not calculate fixed capsule feeding ratios based on active ingredients, leading to mass quality incidents where single capsules contained excessive or insufficient active components. Multiple batches of finished products were detained by Spanish drug regulatory authorities during sampling inspections and could not be launched for sale. Meanwhile, Pueraria harvested by individual farmers carried excessive soil heavy metals and field pesticide residues that could not be fully removed by routine water washing, pushing many pesticide residue indicators close to the EU EC396 limit thresholds.
Puerarin is a thermosensitive isoflavone component prone to oxidative hydrolysis at temperatures above 62°C. Original manufacturers adopted long-duration ethanol reflux extraction at 75–82°C for over 3.5 hours, leading to a puerarin degradation loss of more than 29% under high-temperature conditions. Even with high-quality Hubei wild Pueraria as raw material, finished puerarin content struggled to meet stable standards. High-temperature extraction simultaneously precipitated large amounts of native Pueraria starch, crude fiber and free colloidal impurities, which not only lowered the proportion of active ingredients but also created hidden risks of precipitation and formula turbidity in oral liquids during low-temperature storage. Traditional open extraction equipment lacked closed solvent recovery devices, resulting in finished ethanol residue generally exceeding 6300 ppm, far above the Spanish internal control limit of ≤2800 ppm for pharmaceutical raw materials. After being used for soft capsule production, the gelatin capsule shells absorbed moisture, softened and leaked, pushing the single-product rejection rate above 27%.
After extraction and concentration, original manufacturers uniformly produced crude powder via conventional spray drying without separate modification production lines for different dosage forms. The same crude powder was supplied to both capsule filling and oral liquid blending lines, triggering two types of mass production malfunctions:
1. Capsule production section: Uneven particle size with excessive fine powder, powder repose angle over 48°, electrostatic agglomeration and caking of powder materials. Automatic capsule hoppers frequently bridged and clogged, requiring cleaning every 50 minutes on average. Single capsule filling error peaked at 8.1%, failing to comply with the Spanish Pharmacopoeia internal control standard of ±2%.
2. Oral liquid production section: Natural Pueraria flavonoids exhibit extremely poor water solubility. Without cyclodextrin inclusion modification, crude powder caused cloudy solutions when mixed at room temperature, with brown flocculent precipitation forming after 5–7 days of storage at 4°C, destroying the colloidal system of oral liquids and rendering entire batches unqualified for warehousing retention samples.
The Spanish pharmaceutical plant’s mature formula mixes Pueraria Mirifica extract with citric acid, B vitamins and botanical fruit acids to produce oral liquids. Crude extracts retained large volumes of unremoved native Pueraria starch and macromolecular colloids. During low-temperature storage, starch gradually absorbed water and gelatinized, undergoing complexation reactions with organic acids. Finished products turned from light yellow to dark brown after 30 days of storage, failing to meet the EU mandatory 24-month shelf life standard. The pharmaceutical plant adjusted auxiliary material proportions and replaced food-grade fruit acid raw materials four times, which only slightly delayed discoloration without eliminating impurity risks at the raw material source, trapping formula optimization in a bottleneck.
Spanish drug regulatory authorities and customs require raw materials to be accompanied by full documentation including Hubei GAP field planting ledgers, field pesticide application records, SGS 226-item pesticide residue test reports per EC396 standards, English COA, REACH compliance declarations, and EUDR full-chain traceability files. Original manufacturers could only provide simple domestic self-inspection reports, with massive gaps in raw material traceability and compliance documents. Shipments faced high risks of customs detention upon arrival and could not complete local drug regulatory filing for importers.
HiSiaddi set up a special task force consisting of plant extract extraction engineers, EU compliance specialists and formulation docking staff. It screened two mid-to-high-end plant extract manufacturers with designated Hubei Pueraria collection qualifications and closed low-temperature refining production lines, and implemented the project in five phases: designated contracted GAP Pueraria raw material sourcing, low-temperature staged gradient extraction, multi-stage resin deep impurity removal, specialized powder modification by dosage form, and full-chain EU compliance filing. The entire process was divided into three rounds of repeated sampling and cross-border testing & adjustment: 100g laboratory samples, 90kg pilot production, and large-scale mass production.
HiSiaddi conducted on-site inspections of high-altitude standardized wild Pueraria planting areas in Enshi, Hubei, and signed annual exclusive Pueraria harvesting agreements with three licensed large-scale planting cooperatives. Only wild-domesticated Pueraria with a full 3-year growth cycle was selected for harvesting after above-ground stems and leaves withered each autumn and winter. Rotten tubers, fast-growing starch Pueraria and moldy residual materials were manually sorted out. Each batch of Pueraria raw materials came with field pesticide use ledgers, plot planting filing certificates and pre-production quality inspection documents before entering factories. Raw materials were tested for intrinsic total isoflavone content prior to factory admission; entire batches with intrinsic isoflavone levels below 7% were rejected. This completely eliminated mixing of low-quality Pueraria from multiple origins, fixed the baseline value of raw material active ingredients from the source, and avoided wide fluctuations in finished product indicators.
The traditional high-temperature full-reflux extraction process was fully replaced with a customized route combining normal-temperature gradient percolation, low-temperature staged ethanol extraction, negative-pressure low-temperature concentration, and series refining via AB-8 and D101 macroporous resins. Extraction temperature was strictly controlled at 40–42°C with three-stage gradient ethanol fractional extraction under fully closed and light-shielded production conditions, cutting puerarin high-temperature degradation loss to below 5.5%. Multi-stage resins sequentially removed native starch, crude fiber, macromolecular colloids and other impurities, stabilizing finished total isoflavones at 39.9%–40.7% and puerarin at 22.1%–22.9%, precisely hitting the client’s two core content indicators. A three-stage closed rectification ethanol recovery system was installed to control finished solvent residue within ≤2720 ppm, below the Spanish internal control limit for pharmaceutical raw materials, thoroughly resolving the softening and leakage issues of soft capsule gelatin shells.
Leveraging the cooperating manufacturers’ newly added nitrogen-sealed air jet milling and low-temperature β-cyclodextrin filler-free inclusion modification production lines, two special powder grades were separately developed:
1. Refined powder for pharmaceutical capsules: After low-temperature vacuum drying, ultrafine grinding under nitrogen protection optimized the powder repose angle to 32°±2°, delivering uniform round particles with controlled fine powder ratio. No anti-caking agents or fillers were added throughout production, offering excellent powder fluidity compatible with high-speed automatic capsule filling and precise filling volume control.
2. Cold-water instant modified powder for oral liquids: Produced at low temperature without starch or maltodextrin additives via β-cyclodextrin molecular inclusion modification technology. Post-modification flavonoid water solubility increased by over a hundred times, enabling instant full dissolution in cold room-temperature water, with crystal-clear solutions free of precipitation and stratification after 90 days of sealed storage at 4°C, perfectly matching sterile oral liquid formula production requirements.
On the raw material side, multi-stage resin refining deeply removed starch, colloids and trace oxidation-promoting metal impurities to eliminate discoloration triggers at the source. On the formula side, HiSiaddi remotely coordinated the Spanish pharmaceutical plant’s R&D team to optimize feeding procedures: Pueraria Mirifica extract, fruit acids and vitamin auxiliary materials were separately pre-mixed and fed in batches to avoid direct complexation reactions between impurities and organic acids. After optimization, finished products showed no browning or turbidity after 90-day accelerated stability retention tests, with active ingredient loss controlled within 3%, smoothly passing EU shelf-life stability testing.
HiSiaddi compiled full Enshi GAP planting process archives, Pueraria origin traceability documents, SGS 226-item pesticide residue full test reports per EC396 standards, English COA with HPLC chromatograms, REACH product compliance DoC statements, English MSDS, and EUDR full-chain traceability dossiers. All documents were filed in both Chinese and English per Spanish pharmaceutical regulatory formats, assisting the client with pre-review and filing of raw materials with local Spanish importers in advance.
After six rounds of cross-border sample delivery, full testing by an authoritative third-party laboratory in Spain and a 32-day consecutive pilot mass production acceptance in the client’s GMP workshop, both customized raw materials passed pre-entry review by Spanish drug regulatory authorities. The first batch of 4.8 tons of finished products was vacuum-packed with nitrogen-filled aluminum foil bags and shipped from Shanghai Port to Barcelona. Random customs inspections in Spain cleared the goods for warehousing in one go. After formal production launch, the capsule production line operated stably continuously, with single capsule filling error controlled within ±1.7% and product rejection rate plummeting from the original 27.3% to 0.98%. All batches of oral liquid retained samples remained clear without precipitation during low-temperature storage. The new product launch delayed by 76 days successfully completed registration with Spanish drug regulatory authorities and rolled out across national chain pharmacies and private wellness institutions in Spain.
Spanish BioSalud signed a long-term fixed-price framework procurement order for an annual volume of 16.5 tons, including 9.7 tons of special refined powder for capsules and 6.8 tons of water-soluble modified powder for oral liquids, with monthly production split into 11 batches throughout the year. After stable cooperation, the client added customized procurement of organic-grade wild Pueraria Mirifica extract the following year, with HiSiaddi fully coordinating origin control, process debugging, sample testing and compliance filing. Compared with raw materials imported from France, comprehensive customized procurement costs dropped by 30.8%, while cross-border ocean transit time was shortened from 79 days to 20 days, drastically cutting the client’s raw material stocking cycle and working capital occupation. Endorsed by this mid-to-high-end Spanish pharmaceutical brand, domestic cooperating manufacturers refined standardized customized production lines for Pueraria Mirifica extract, subsequently securing annual raw material orders from three equivalent pharmaceutical enterprises in Portugal and Italy, breaking free from the low-price internal competition of domestic low-grade crude Pueraria powder.
Most small and medium-sized domestic plant extract enterprises focus on mass production of low-priced bulk raw materials with scattered raw material storage and solid outdated production processes. They lack refined customized R&D capabilities aligned with EU Pharmacopoeia standards and systematic research on the thermosensitive properties of puerarin, powder modification, and annually updated EU pesticide residue and traceability regulations. Mid-to-high-end European pharmaceutical enterprises represented by Spanish BioSalud specialize in terminal formulation R&D and are well-versed in strict local drug regulatory and mass production specifications, yet lack familiarity with quality stratification of China’s Pueraria producing areas and uneven factory processes. Blind independent direct sourcing easily leads to customized product failures, delayed new product launches and substantial economic losses.
Relying on upstream high-quality origin resources, composite technical reserves covering plant extracts and formulations, and accumulated compliance resources for multiple European and American countries, HiSiaddi built a closed-loop full-chain customized service covering controlled GAP raw material sourcing, customized low-temperature extraction and refining, dosage-form differentiated powder modification, terminal formula collaborative optimization, and one-stop cross-border compliance support. Acting as a neutral third-party foreign trade service provider, it bridges technological and regulatory gaps between overseas customized demands and domestic production capacity. It not only helps mid-to-high-end overseas pharmaceutical enterprises avoid various cross-border procurement customization risks but also empowers high-quality domestic plant extract manufacturers to enter the high-end European pharmaceutical natural raw material supply chain, creating an implementable customized service model for domestic medicinal and edible homologous extracts to enter high-end European pharmaceutical markets.
If you require more customized service solutions, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
